On May 5, 2024, a team of researchers including Jing Wang, Ling Ma, Kai Lv, Rui Zhou, Dongrong Yi, Qian Liu, Yongxin Zhang, Xiaoyu Li, Tingting Cheng, and Shan Cen from the Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, collaborated with scientists from RinuaGene Biotechnology Co., Ltd., including Qixin Wang, Yi Wang, Tingting Zhang, Jinming Zhang, Chunjian Huang, Yijie Dong, and Weiguo Zhang, published a research paper titled "Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV related malignancies" in Molecular Therapy (impact factor: 12.91). In this study, the research team have successfully developed a novel mRNA-based therapeutic HPV vaccine, named mHTV-03E2, targeting high-risk HPV-associated malignancies.
Human Papillomavirus (HPV) infections, particularly HPV 16 and 18, are implicated in numerous human cancers. Despite the availability of preventive vaccines for high-risk HPV strains, there remains an urgent need for therapeutic HPV vaccines to address existing high-risk HPV infections and lesions.
Utilizing lipid nanoparticle (LNP) technology for efficient mRNA delivery, the team developed the mHTV-03E2 vaccine targeting the E2/E6/E7 proteins of both HPV16 and HPV18. The vaccine significantly induced antigen-specific cellular immune responses, leading to notable infiltration of CD8+ T cells and enhanced cytotoxicity within tumors. This resulted in remarkable tumor regression and prolonged animal survival in a dose-dependent manner.
Furthermore, sustained T cell immunity against HPV16/18 E6/E7 antigens was observed for up to 4 months post-vaccination, indicating the vaccine's potential for preventing tumor relapse. Additionally, when combined with immune checkpoint blockade therapy, mHTV-03E2 showed synergistic effects in inhibiting tumor growth and extending animal survival, suggesting promising prospects for combination therapy.
In conjunction with the research study, a set of peptides spanning the HPV16/18 E2, E6 and E7 antigens, each containing 15 amino acid residues overlapping by eight amino acids, were synthesized from SBS Genetech. Since 2000, SBS Genetech has been at the forefront of providing solutions in life sciences. We offer safer, superior quality, and more cost-effective products to preeminent researchers in more than 60 countries, empowering them to make new discoveries in biology. Our products have been widely utilized in academic research, with results often published in leading academic journals like Science, Cell, Cancer Cell, and Cell Metabolism. We firmly believe that through continuous innovation and research, we will continually infuse new vitality and possibilities into the field of life sciences.